H. Lundbeck A/S (VIE:LUNA)

Market Cap	5.52B +7.1%
Revenue (ttm)	3.22B +12.3%
Net Income	510.00M +41.8%
EPS	0.51 +41.7%
Shares Out	n/a
PE Ratio	10.83
Forward PE	6.68
Dividend	0.13 (2.42%)
Ex-Dividend Date	Mar 27, 2025

Volume	n/a
Average Volume	14
Open	5.03
Previous Close	5.00
Day's Range	5.00 - 5.03
52-Week Range	3.13 - 5.32
Beta	n/a
RSI	49.34
Earnings Date	Feb 4, 2026

About H. Lundbeck

H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat major depressive disorder and schizophrenia; Vyepti for migraine prevention; and Cipralex/Lexapro for depression. It also provides Northera for symptomati...

• Industry: Pharmaceutical Preparations
• Founded: 1915
• Employees: 5,700
• Stock Exchange: Vienna Stock Exchange
• Ticker Symbol: LUNA

Financial Performance

In 2024, H. Lundbeck's revenue was 22.00 billion, an increase of 10.51% compared to the previous year's 19.91 billion. Earnings were 3.14 billion, an increase of 37.25%.

Financial numbers in DKK